Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Jiangdong Qiu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-9406-4863; OpenAlex author ID A5102711107. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2019: 1 paper · 2020: 4 papers · 2021: 4 papers · 2022: none · 2023: 7 papers · 2024: 5 papers · 2025: 2 papers

Papers 23

  1. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  2. Feasibility of simplified Patlak parametric imaging with scaled population-based input function on pancreatic cancer. Co-author DOI 10.1186/s40658-025-00758-z↗
  3. E3 ubiquitin ligase RBCK1 confers ferroptosis resistance in pancreatic cancer by facilitating MFN2 degradation. Co-author DOI 10.1016/j.freeradbiomed.2024.05.031↗
  4. Multiomics integration reveals NETosis heterogeneity and TLR2 as a prognostic biomarker in pancreatic cancer. Co-author DOI 10.1038/s41698-024-00586-x↗
  5. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3638↗
  6. CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. Co-author DOI 10.1186/s13046-024-03201-w↗
  7. Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer. Co-author DOI 10.2147/cmar.s465098↗
  8. Prognostic value of preoperative [68 Ga]Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological c… First author DOI 10.1007/s00259-022-06100-4↗
  9. Comparing the clinical value of baseline [68 Ga]Ga-FAPI-04 PET/CT and [18F]F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the… First author DOI 10.1007/s00259-023-06297-y↗
  10. Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer. Co-author DOI 10.1007/s13402-023-00836-3↗
  11. mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune mic… Co-author DOI 10.1016/j.canlet.2022.216020↗
  12. Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment. Co-author DOI 10.1016/j.canlet.2023.216423↗
  13. PRKRA promotes pancreatic cancer progression by upregulating MMP1 transcription via the NF-κB pathway. Co-author DOI 10.1016/j.heliyon.2023.e17194↗
  14. Epidemiology of pancreatic cancer: New version, new vision. Co-author DOI 10.21147/j.issn.1000-9604.2023.05.03↗
  15. Novel therapies targeting hypoxia mechanism to treat pancreatic cancer. First author DOI 10.21147/j.issn.1000-9604.2021.02.09↗
  16. Comprehensive Analysis of Autophagy-Associated lncRNAs Reveal Potential Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.596573↗
  17. The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. Co-author DOI 10.3390/cells10030497↗
  18. [Challenges and stratigies of neoadjuvant therapy for pancreatic cancer]. Last author DOI 10.3760/cma.j.cn112137-20201225-03469↗
  19. Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.05.003↗
  20. Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic E. coli Infection Cause Pancreatic Cancer Progressi… Co-author DOI 10.1155/2020/2340124↗
  21. Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. Co-author DOI 10.1186/s12935-020-1147-9↗
  22. [The guideline for neoadjuvant therapy of pancreatic cancer in China (2020 edition)]. Co-author DOI 10.3760/cma.j.cn112139-20200708-00549↗
  23. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination? Co-author DOI 10.1002/cam4.2384↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 21 shared papers, 2019–2025 · strength 3.46
  2. Wenhao Luo · 15 shared papers, 2019–2025 · strength 2.39
  3. Yueze Liu · 14 shared papers, 2019–2025 · strength 2.23
  4. Jinxin Tao · 9 shared papers, 2023–2025 · strength 1.63
  5. Gang Yang · 10 shared papers, 2019–2024 · strength 1.43
  6. Lei You · 9 shared papers, 2019–2024 · strength 1.25
  7. Fangyu Zhao · 8 shared papers, 2019–2024 · strength 1.09
  8. Hua Huang · 6 shared papers, 2021–2025 · strength 0.96
  9. Jianchun Xiao · 6 shared papers, 2020–2025 · strength 0.94
  10. Zhe Cao · 7 shared papers, 2019–2024 · strength 0.90
  11. Dan Su · 5 shared papers, 2023–2024 · strength 0.89
  12. Ruobing Wang · 4 shared papers, 2023–2024 · strength 0.73
  13. Yupei Zhao · 5 shared papers, 2019–2024 · strength 0.72
  14. Guangyu Chen · 5 shared papers, 2020–2024 · strength 0.70
  15. Mengyu Feng · 4 shared papers, 2019–2023 · strength 0.58
  16. Zhixin Hao · 3 shared papers, 2023–2025 · strength 0.57
  17. Li Huo · 3 shared papers, 2023–2025 · strength 0.57
  18. Tao Liu · 3 shared papers, 2024–2025 · strength 0.55
  19. Yifan Fu · 3 shared papers, 2024–2025 · strength 0.55
  20. Jun Wang · 3 shared papers, 2023–2025 · strength 0.53
  21. Wenming Wu · 2 shared papers, 2023–2025 · strength 0.40
  22. Yuanyang Wang · 2 shared papers, 2024–2025 · strength 0.39
  23. T P Zhang · 2 shared papers, 2020–2021 · strength 0.38
  24. Wenhao Luo · 2 shared papers, 2023–2024 · strength 0.35
  25. Dan Su · 2 shared papers, 2024 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.